

# #4039: THE ADJUDICATION RATES BETWEEN READERS IN BLINDED INDEPENDENT CENTRAL REVIEW (BICR) OF ADVANCED ESOPHAGEAL CANCER TRIALS WITH OR WITHOUT IMMUNE CHECKPOINT INITIATORS AS FIRST LINE THERAPY

Authors: Yan Liu<sup>1</sup>, Yi Wang<sup>1</sup>, Antoine Iannessi<sup>1</sup>

## BACKGROUND

Using RECIST 1.1 for the response assessment in esophageal cancer is challenging:

- ✓ It excludes certain examines such as the use of barium meal and endoscopy.
- ✓ Esophageal lesions could be infiltrative in a cavity organ, and difficult to measure reliably especially after treatment.
- ✓ It can even be more difficult for independent central readers, as they are often blinded to patient clinical symptoms and outcomes.

## OBJECTIVES

- TO DOCUMENT THE PROPORTION OF READER DISCREPANCIES
- TO EVALUATE READER PERFORMANCE
- TO PROVIDE SUGGESTIONS FOR THE REDUCTION OF READ INCONSISTENCY


## METHODS

We analyzed:

- ✓ **4 esophageal cancer BICR trials** including **1,875 patients** (8,501 time-points), involving **14 radiologists**;
- ✓ The adjudication rates and the endorsement rates of the pooled dataset

## CONCLUSIONS

We provided **benchmarks** for monitoring reader performance with double reads in novel esophageal cancer trials with or without immune checkpoint inhibitors. The discordances of baseline **lesion selection and lesion measurement** in follow up visits are the main reasons triggering adjudications in esophageal cancer central reading.





*Appropriate reader training and monitoring are solutions which cannot only mitigate a large portion of the commonly encountered reading errors but also help to reach higher consensus on lesion selection and measurement between readers.*

Contact: yan.liu@mediantechnologies.com

## RESULTS

Trials had an average adjudication rate of **45.28%** [42.60%-47.99%], while readers endorsement rates ranged [23.1%-81.6%].

Discordance reasons



Discordance due to target lesion selection and measurement

## FUTURE DIRECTIONS FOR RESEARCH

- To investigate the root cause of discordance on primary tumor (esophageal lesion) selection and assessment
- To evaluate the impacts of such discordance on the overall response per RECIST 1.1